Genes Co-amplified with MYCN in Neuroblastoma: Silent Passengers or Co-determinants of Phenotype?

Overview

Journal Cancer Lett

Specialty Oncology

Date 2003 Jul 26

PMID 12880964

Citations 12

Authors

Debbie Scott

Joanna Elsden

Andrew Pearson

John Lunec

Affiliations

Soon will be listed here.

Abstract

Amplification of the MYCN oncogene in neuroblastoma is associated with poor prognosis. The amplified unit of DNA can be up to 1 Mb in size and so could contain additional genes that affect tumour phenotype. Identification of such genes may assist in optimising the determination of prognosis, and could provide new targets for treatment. Three genes have so far been identified, which are frequently co-amplified with MYCN in neuroblastoma, DDX1, NAG and N-cym. In this review, the known or putative properties of the protein products of the genes are discussed, and their possible roles in determining tumour behaviour are assessed.

Citing Articles

Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.

Schwalbe E, Lindsey J, Danilenko M, Hill R, Crosier S, Ryan S Neuro Oncol. 2024; 27(1):222-236.

PMID: 39377358 PMC: 11726341. DOI: 10.1093/neuonc/noae178.

Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.

Wang H, Wang X, Xu L Ital J Pediatr. 2023; 49(1):145.

PMID: 37904225 PMC: 10617224. DOI: 10.1186/s13052-023-01549-x.

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.

Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P Cancers (Basel). 2022; 14(18).

PMID: 36139583 PMC: 9496712. DOI: 10.3390/cancers14184421.

CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma.

Wang H, Wang X, Xu L, Lin Y, Zhang J Dis Markers. 2022; 2022:1560199.

PMID: 35937942 PMC: 9352476. DOI: 10.1155/2022/1560199.

High Grade of Amplification of Six Regions on Chromosome 2p in a Neuroblastoma Patient with Very Poor Outcome: The Putative New Oncogene .

Ognibene M, Amoroso L, Melchionda F, Cangelosi D, Zara F, Parodi S Cancers (Basel). 2021; 13(22).

PMID: 34830942 PMC: 8616235. DOI: 10.3390/cancers13225792.